9 completed, 6 recruiting, 5 active not recruiting, 3 terminated. 27 Phase 2, 8 Phase 1.
Follow AL Amyloidosis: new trials by email Literature Review of AL Amyloidosis trials Research Report on AL Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004) QLS4131 - AL Amyloidosis | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-07-20 | 2026-08-07 |
| A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). Teclistamab - Multiple Myeloma, AL Amyloidosis | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 30 | 2026-05-22 | 2026-08-03 |
| A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis Teclistamab - AL Amyloidosis | Phase 2 | Active not recruiting | European Myeloma Network B.V. | 30 | 2025-07-02 | 2026-07-20 |
| Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis Eque-cel CAR-T Therapy - AL Amyloidosis | Phase 2 | Not yet recruiting | Nanjing IASO Biotechnology Co., Ltd. | 17 | 2025-07-01 | 2025-07-09 |
| Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis Teclistamab (Tec) - AL Amyloidosis | Phase 2 | Recruiting | Peking Union Medical College Hospital | 35 | 2025-06-28 | 2025-07-23 |
| Teclistamab in Previously Treated AL Amyloidosis Teclistamab (Tec) - AL Amyloidosis | Phase 2 | Recruiting | Peking Union Medical College Hospital | 30 | 2025-05-21 | 2025-05-25 |
| Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis Elranatamab - AL Amyloidosis | Phase 1 / Phase 2 | Recruiting | Dana-Farber Cancer Institute | 49 | 2024-11-01 | 2026-08-19 |
| Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis Belantamab mafodotin 2.5 mg/kg (8 weeks), Belantamab mafodotin 1.9 mg/kg (8 weeks), Belantamab mafodotin 1.4 mg/kg (12 weeks) - AL Amyloidosis, Amyloidosis | Phase 1 / Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 37 | 2024-02-15 | 2026-08-19 |
| Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) Venetoclax, Dexamethasone, Daratumumab - AL Amyloidosis, Light Chain (AL) Amyloidosis | Phase 1 / Phase 2 | Withdrawn | Alfred Chung, MD | 2024-01-08 | 2025-03-06 | |
| Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial Bone Marrow Aspiration, Daratumumab, Echocardiography Test - AL Amyloidosis | Phase 2 | Recruiting | Mayo Clinic | 96 | 2023-09-06 | 2026-10-01 |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg - AL Amyloidosis | Phase 1 / Phase 2 | Active not recruiting | Columbia University | 53 | 2022-10-26 | 2026-10-08 |
| Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy Isatuximab - AL Amyloidosis | Phase 2 | Unknown | Intergroupe Francophone du Myelome | 46 | 2022-02-11 | 2024-03-06 |
| Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis ZN-d5 - Amyloidosis, AL Amyloidosis | Phase 1 / Phase 2 | Completed | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 18 | 2021-11-30 | 2024-09-19 |
| COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies A single "booster" dose of the Moderna mRNA COVID-19 vaccine - Multiple Myeloma, AL Amyloidosis | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 119 | 2021-08-17 | 2023-12-20 |
| Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis daratumumab and pomalidomide - AL Amyloidosis | Phase 2 | Terminated | Fondazione IRCCS Policlinico San Matteo di Pavia | 27 | 2021-06-23 | 2025-02-20 |
| Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab Daratumumab SC, Pomalidomide, Dexamethasone - Amyloid, AL Amyloidosis | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 15 | 2021-04-14 | 2026-02-27 |
| A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis Belantamab mafodotin - AL Amyloidosis | Phase 2 | Completed | Stichting European Myeloma Network | 35 | 2021-02-26 | 2026-07-31 |
| A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab - AL Amyloidosis | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 25 | 2020-03-18 | 2025-03-05 |
| Ixazomib Maintenance Study in Patients With AL Amyloidosis Ixazomib, Dexamethasone - AL Amyloidosis | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2018-08-02 | 2025-12-04 |
| Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis Siltuximab, The M.D. Anderson Symptom Inventory (MDASI) - Multiple Myeloma, AL Amyloidosis | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2017-12-14 | 2026-11-05 |
Showing 20 of 27. Sign in to see all of them.
Immunoglobulin Light-chain Amyloidosis (27) · Amyloidosis (6) · Alzheimer Disease (3) · Multiple Myeloma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1) · Proteostasis Deficiencies (1)
Immune System Diseases (27) · Immunoproliferative Disorders (27) · Lymphoproliferative Disorders (27) · Metabolic Diseases (27) · Neoplasms (27) · Neoplasms by Histologic Type (27) · Nutritional and Metabolic Diseases (27) · Neoplasms, Plasma Cell (26) · Paraproteinemias (26) · Proteostasis Deficiencies (26) · Amyloidosis (21) · Blood Protein Disorders (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Brain Diseases (3)
Dexamethasone (9) · daratumumab (7) · pomalidomide (5) · Calcium Dobesilate (3) · birtamimab (3) · ixazomib (3) · Bendamustine Hydrochloride (2) · Focal Adhesion Protein-Tyrosine Kinases (2) · belantamab mafodotin (2) · venetoclax (2) · Biological Assay (1) · Bortezomib (1) · Cyclophosphamide (1) · Drug Evaluation (1) · In Situ Hybridization (1)
Prothena Biosciences Ltd. (3) · Boston Medical Center (2) · Columbia University (2) · Memorial Sloan Kettering Cancer Center (2) · Peking Union Medical College Hospital (2) · Alexion Pharmaceuticals, Inc. (1) · Alfred Chung, MD (1) · Barbara Ann Karmanos Cancer Institute (1) · Dana-Farber Cancer Institute (1) · European Myeloma Network B.V. (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Icahn School of Medicine at Mount Sinai (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Intergroupe Francophone du Myelome (1) · K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (1)
United States (17) · Italy (6) · France (5) · Greece (5) · Australia (4) · China (4) · Germany (4) · Israel (3) · Spain (3) · United Kingdom (3) · Austria (2) · Netherlands (2) · Cyprus (1)
Vaishali Sanchorawala, MD (2) · Alfred Chung, MD (1) · Giada Bianchi (1) · Gunjan Shah (1) · Heather Landau, MD (1) · Jeffrey A. Zonder, M.D. (1) · Keren Osman, MD (1) · Larry Anderson, MD (1) · Murielle Roussel, MD (1) · Peng Liu (1) · Rajshekhar Chakraborty, MD (1) · Suzanne Lentzsch, MD, PhD (1)
PMID 40226119, PMID 27381904, PMID 31978210, PMID 32083996
R21CA288898 (1)